Reported 5 months ago
A new report published in JAMA reveals a significant increase in the use of weight-loss drugs, specifically GLP-1 receptor agonists like Wegovy and Ozempic, among adolescents and young adults aged 12 to 25 in the U.S. The study found that monthly use of these medications surged nearly 600% from 2020 to 2023 in this age group, with over 31,000 children aged 12 to 17 and more than 162,000 individuals aged 18 to 25 using them in 2023 alone. Despite concerns about long-term safety, effectiveness, and accessibility, these drugs are being prescribed more frequently to help combat obesity and related health issues in young people.
Source: YAHOO